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Background: High grade serous ovarian cancer is one of the poorly characterized malignancies. This study aimed
to elucidate the mutational events in Malaysian patients with high grade serous ovarian cancer by performing
targeted sequencing on 50 cancer hotspot genes.
Results: Nine high grade serous ovarian carcinoma samples and ten normal ovarian tissues were obtained from
Universiti Kebangsaan Malaysia Medical Center (UKMMC) and the Kajang Hospital. The Ion AmpliSeq™ Cancer Hotspot
Panel v2 targeting “mutation-hotspot region” in 50 most common cancer-associated genes was utilized. A total of 20
variants were identified in 12 genes. Eleven (55%) were silent alterations and nine (45%) were missense mutations. Six
of the nine missense mutations were predicted to be deleterious while the other three have low or neutral protein
impact. Eight genes were altered in both the tumor and normal groups (APC, EGFR, FGFR3, KDR, MET, PDGFRA, RET and
SMO) while four genes (TP53, PIK3CA, STK11 and KIT) were exclusively altered in the tumor group. TP53 alterations were
present in all the tumors but not in the normal group. Six deleterious mutations in TP53 (p.R175H, p.H193R, p.Y220C,
p.Y163C, p.R282G and p.Y234H) were identified in eight serous ovarian carcinoma samples and none in the normal
group.
Conclusion: TP53 remains as the most frequently altered gene in high grade serous ovarian cancer and Ion Torrent
Personal Genome Machine (PGM) in combination with Ion Ampliseq™ Cancer Hotspot Panel v2 were proven to be
instrumental in identifying a wide range of genetic alterations simultaneously from a minute amount of DNA. However,
larger series of validation targeting more genes are necessary in order to shed a light on the molecular events
underlying pathogenesis of this cancer.
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Detecting cancer at an early stage or tackling it at the late
stage in an efficient way is always a challenge in clinical
care. Molecular approaches are now used widely at many
stages of cancer management and continue to expand
with the increase in the understanding of cancer biology
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article, unless otherwise stated.Cancer treatment has been revolutionised by the demand
in molecular diagnostics to detect standard-of-care muta-
tions with druggable targets and to predict drug response
and survival [1]. The next generation sequencing (NGS)
approach has become a powerful platform to complement
clinical diagnosis and assist in therapeutic decision-making
in cancer due to its improved sensitivity in mutation
detection and fast-turnaround time compared to current
gold standard methods. It has also the ability to simultan-
eously sequence multiple cancer-driving genes in a single
assay [1].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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has been the gold standard for mutation analysis in can-
cer diagnostics [2]. However, it has a relatively low sensi-
tivity, lower throughput with higher turnaround time
and overall cost [3]. The emergence of NGS, three de-
cades later, has overcome these drawbacks via its ability
to massively sequence millions of DNA segments in par-
allel hence lowering the cost of sequencing per base and
achieve a faster turnaround time and superior sensitivity
in mutation detection [3]. As of now, whole genome se-
quencing is still too expensive to be used for routine
diagnostics hence the option to perform targeted se-
quencing of exon coding regions or a subset of genes of
interest offered by NGS is an attractive approach [4]. In
comparison with the single gene analysis which is com-
monly done with the Sanger approach, the application of
NGS in cancer diagnostics allows the analysis of multiple
genes to identify druggable mutations and also to gener-
ate a more complete genotype of the cancer.
This study focused on ovarian cancer which is the
fourth most frequently diagnosed cancer among Malay-
sian women, with 656 cases reported in 2007 [5]. Glo-
bally, this devastating disease is the third most common
gynecological malignancy with around 225,000 new
cases diagnosed in 2008 and 46.7% of them contributed
by the Asian population [6]. Ovarian cancer consists of a
heterogeneous group of tumors with distinct histological
features, molecular characteristics and clinical behavior
[7,8]. The most common subtype of epithelial ovarian
cancers is the serous carcinoma [9]. Malpica and col-
leagues described a 2-tier system for grading serous ovar-
ian carcinoma i.e. as a high grade (formerly grade 2 and 3
tumors) or low grade (formerly grade 1), based mainly on
the degree of nuclear atypia and mitotic rate [10]. This
grading system has resulted in an effective classification of
serous ovarian carcinoma as it has been proven that the
low and high grade serous ovarian cancers are not only
histologically different, but also exhibit distinct molecular,
epidemiologic and clinical features [11].
Low grade serous ovarian carcinoma patients are youn-
ger than those with high grade counterpart, with age
range from 45–57 year old and 55–65 year old, respect-
ively [10]. In a study that compared consequence between
both types of serous ovarian carcinomas using the 2-tier
system, patients with low grade tumors have better sur-
vival and mortality due to disease was more rapid with
high grade tumors [10]. With high grade tumors, the me-
dian survival was 1.7 years compared to 4.2 years for pa-
tients with low grade tumors [10].
From genetic perspectives, the low grade serous ovar-
ian carcinoma is characterized by mutations in KRAS,
BRAF or ERBB2 genes; whereby approximately 66% of
cases have mutations in at least one of these genes with
the ERBB2 being the least frequently mutated [12-14].Mutual exclusivity is observed in these three genes; a
tumor with a KRAS mutation will not have a mutation
of the other two genes, and vice versa [9]. Compara-
tively, less is known about the pathogenesis of high
grade serous carcinoma. Mutations of KRAS, BRAF, or
ERBB2 are infrequently detected in high grade carcin-
oma [12-14]. On the contrary, 80% of high grade tumors
harbor TP53 mutation and various DNA copy number
aberrations [15-17]. In addition, a specific KRAS muta-
tion found in low grade serous ovarian cancer has been
shown to be associated with shorter survival, further
adding a clinical value of NGS in cancer research [18].
Thus it is pertinent to improve our understanding of the
high grade serous ovarian cancer in order to predict the
prognosis of patients or for making therapeutic deci-
sions. This study was undertaken to characterize the
gene alterations in high grade serous ovarian cancer in
Malaysian patients by performing targeted sequencing
on 50 cancer genes with established biological functions
in cancer.Methods
Clinical specimens
Nine high grade serous ovarian carcinoma samples
were obtained from newly diagnosed patients undergo-
ing total abdominal hysterectomy with bilateral salphingo-
oophorectomy (TAHBSO) at the Universiti Kebangsaan
Malaysia Medical Center (UKMMC) and the Kajang Hos-
pital. Ten normal ovarian tissues were also obtained from
patients undergoing TAHBSO for benign gynecological
diseases. The study was approved by the UKM Medical
Research Ethics Committee and written informed consent
was taken from the participants. None of patients had re-
ceived chemotherapy or radiotherapy. The tissues were
kept frozen in liquid nitrogen until subjected to cryosec-
tioning. Hematoxylin & Eosin staining (H&E) was per-
formed and the slides were reviewed by the pathologist.
Only tissue sections that contained more than 80% tumor
cell nuclei with less than 20% necrosis were included in
this study. The normal specimens were confirmed to be
free from tumor or inflammatory cells.DNA extraction and quality assessments
DNA was extracted from the tissues using the DNAeasy
Blood and Tissue Kit (Qiagen, Valencia, CA). Nucleic
acid quality and quantity were assessed using the Qubit
Fluorometer (Invitrogen, Carlsbad, CA, USA), Nano-
Drop 2000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE) and agarose gel electrophoresis. The
highly intact and non-degraded RNA-free genomic DNA
was subjected to library preparation prior to sequencing.
We used 10 ng of DNA of each sample for the Ion Ampli-
seq library preparation.
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We used the Ion AmpliSeq™ Cancer Hotspot Panel v2
(Life Technologies, Guilford, CT) which allows the
characterization of mutational hotspots in 50 cancer-
related genes (Additional file 1: Table S1). Library prep-
aration was performed using the Ion Ampliseq Library
Kits 2.0 protocol. DNA amplification was carried out
using the Ion AmpliSeq Cancer Hotspot Panel v2 and
the 5x Ion AmpliseqHiFi Master Mix. Sequencing adap-
tors with short stretches of index sequences (barcodes)
that enable sample multiplexing were ligated to the
amplicons using the Ion Express Barcode Adaptors Kit
(Life Technologies, Guilford, CT). The adapters-ligated
amplicons (library) were purified using the Agencourt
AMPure XP reagent (BD Biosciences, USA). The library
was subjected to the second round of amplification using
the Platinum PCR SuperMix High Fidelity and Library
Amplification Primer Mix. The amplified library under-
went three rounds of purification using the Agencourt
AMPure XP reagent. The library was then quantified
using the Bioanalyzer High Sensitivity DNA chip (Agilent
Technologies Inc, Santa Clara, CA). The desired concen-
tration for template preparation on the One Touch instru-
ment was between 15 to 20 pM.
Emulsion PCR and ion torrent PGM™ sequencing
The clonal amplification of the barcoded DNA library
onto the ion spheres (ISPs) was carried out using emul-
sion PCR and the subsequent isolation of ISPs with
DNA was performed using Ion OneTouch 200 Template
Kit v2 DL and Ion OneTouch ES (Life Technologies,
Guilford, CT) as described by the manufacturer. The poly-
clonal percentage and quality of the enriched, template-
positive ISPs was determined using the Ion Sphere Quality
Control Kit (Life Technologies, Guilford, CT). Samples
with polyclonal percentage of less than 30% and enriched,
template-positive ISPs of more than >80% were subjected
for sequencing on the Ion Torrent Personal Genome
Machine (PGM™). Enriched ISPs were subjected to se-
quencing on a 314 v2 Ion Chip (two samples per chip)
using Ion PGM™ Sequencing 200 kit v2 (Life Technolo-
gies, Guilford, CT). A cut-off with a quality score of
Q17 (a quality score of 2% errors, corresponding to 1
base error allowed per 50 bases) was used as a measure
of successful sequencing.
Validation using sanger sequencing
Variants identified were validated using the Sanger se-
quencing method. Primers corresponding to the alteration
sites were purchased from Life Technologies. The primer
pairs chosen are HS00424883_CE, HS00432201_CE and
HS00346578_CE. Briefly, PCR products were generated
and cycle sequencing was performed using the Big Dye
Terminator V3.1 reagent (Life Technologies, Guilford,CT). The cycle sequencing products were then processed
using ethanol precipitation and sequencing was carried
out using the ABI 3130xl capillary electrophoresis (Life
Technologies, Guilford, CT). The results were analyzed
using the Basic Local Alignment System Tool (BLAST).
Bioinformatics analysis
Read mapping and variants calling
Data from sequencing runs from Ion Torrent PGM™
were automatically transferred to the Torrent Server
hosting the Torrent Suite Software that processed the raw
voltage semiconductor sequencing data into DNA base
calls. The Torrent Suite Software utilizes the Torrent
Browser that includes TMAP alignment and Torrent Vari-
ant Caller for alignment and variant detection. Data were
aligned against Human hg19 database. The Ion Reporter
Software (Life Technologies, Guilford, CT) was used to
perform variant calling and mapping.
Filtering of the variants called
A number of steps were used to filter nucleotide variants
identified in the screening; (a) variants that are not an-
notated as pathogenic or probable pathogenic variants
were excluded, (b) variants called in both normal and ser-
ous ovarian cancer genome were excluded and (c) variants
representing probable mapping ambiguities were excluded.
Manual and thorough observation of the variants using the
Integrated Genomic Viewer (IGV) was performed to ex-
clude false variants [19].
Predicting the functional significance of nonsynonymous
mutations
Nonsynonymous missense mutations called were evaluated
by in silico analysis using the TransFIC (TRANSformed
Functional Impact for Cancer (TransFIC) method (http://
bg.upf.edu/transfic/). The method transforms Functional
Impact scores taking into account the differences in basal
tolerance to germline structural number variations of
genes that belongs to the different functional classes. This
transformation allows the use of the scores provided by
well-known tools (SIFT, Polyphen2 and Mutation Asses-
sor) to rank the functional impact of cancer somatic muta-
tions. Mutations with a greater TransFIC values are more
likely to be the cancer drivers.
Cancer genes annotation
Annotation was performed using Oncotator (http://www.
broadinstitute.org/oncotator/), a web application for an-
notating human genomic point mutations and indels with
data relevant to cancer researchers.
Statistical analysis
We utilized the Fisher's exact test to define significant
values in a number of altered genes and total variants
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tingency tables and the GraphPad QuickCalcs Online
Calculator for Scientists (http://www.graphpad.com/quick-
calcs/index.cfm). All p values are two-sided and statistical
significance is denoted by p <0.05.Integrative analysis using the ICGC data portal
We used the International Cancer Genome Consortium
(ICGC) Data Portal [20], a web tool for exploring, visualiz-
ing and analyzing multi-dimensional cancer genomics data,
to interactively explore genetic alterations across samples,
genes and pathways in both the ICGC and our datasets.Results
Epidemiological characteristics
The epidemiological features of the studied subjects are
presented in Table 1. The median age was 57 years for the
patients with serous ovarian cancer and 52 years for the
normal controls.Technical performance of the Ion AmpliSeq™ Cancer
Hotspot Panel v2
The Ion AmpliSeq™ Cancer Hotspot Panel v2 contains
207 primer pairs that cover the “mutation-hotspot region”
in 50 most common cancer-associated genes (Additional
file 1: Table S1). The average sample loading obtained was
83.8% (range 76% - 91%). The total reads ranged from
220,000 – 420,000 reads with an average read length of
112 bp. The details on the loading percentage, number of
reads and sequenced bases for each of the samples are
summarized in Additional file 1: Table S2. On average, the
sequencing coverage for each of the regions is >1000×.Table 1 Clinical information of samples
Description N (%)
Diagnosis (tumour group)
Ovarian serous cyst adenocarcinoma (poorly differentiated)
with anaplasia
1 (11%)
Metastatic high grade serous adenocarcinoma of the ovary 1 (11%)
Bilateral ovarian papillary serous cystadenocarcinoma,
moderately differentiated
1 (11%)
Ovarian serous adenocarcinoma 6 (67%)
Age
< 50 year-old 4 (21%)





Indian 1 (5%)Summary of identified variants
We identified a total of 20 variants in 12 genes. Eight
genes were altered in both the tumor and normal groups
(APC, EGFR, FGFR3, KDR, MET, PDGFRA, RET and
SMO) while four genes (TP53, PIK3CA, STK11 and KIT)
showed presence of alterations in only the cancer sam-
ples. From the total of 20 variants, 11 (55%) were silent
alterations and nine (45%) were missense mutations. Six
of the nine missense mutations were predicted to have
deleterious impact on the proteins while the other three
have low or neutral protein impact. Ten variants were
identified from eight genes in both the tumor and nor-
mal groups (APC, EGFR, FGFR3, KDR, MET, PDGFRA,
RET and SMO). However upon annotation, these variants
resulted in no amino acid changes (silent alteration), have
neutral protein impact or presented in normal population
according to dbSNP database version 38 (minimal allele
frequency >2%).
Base transitions (purine-purine and pyrimide-pyrimidine)
were more frequent than transversions (purine-pyrimidine,
vice versa) (Additional file 1: Figure S1). At least four genes
were altered in each tumor and normal samples. The details
on the variant frequency are shown in Table 2. Our results
showed that TP53 alterations were present in all the tumors
but not in the normal group. We further analyzed the types
of alteration identified in the high grade serous ovarian can-
cer. Table 3 illustrates the variant distribution of the high
grade serous ovarian carcinoma in our cohort of patients.
After manual filtration, eight of the nine high grade serous
ovarian carcinoma samples harboured one deleterious
mutation and all of the deleterious mutations were
found in TP53 as shown in Table 4. The remaining one
high grade serous ovarian carcinoma sample (T7) did
not have any deleterious mutation. There was no deleteri-
ous mutation found in the 10 normal samples (Additional
file 1: Table S3). In addition, the cancer samples showed
significantly more altered genes than the normal group
(average seven altered genes in tumor group versus 4.8
altered genes in normal group; p value = 0.0001). Six
deleterious mutations in TP53 with different codon and
protein changes were identified in eight serous ovarian
carcinoma samples (Figure 1).
Correlation with ICGC datasets
We compared the deleterious mutations obtained from
this study with those in the ICGC Data Portal. Table 5
illustrates the correlations and occurrences of those
deleterious mutations. Among all of the deleterious mu-
tations found in this study, four have been reported in
serous ovarian carcinoma from the consortium (TP53 p.
R175H, p.H193R, p.Y220C, p.Y163C and p.R282G) with
the frequency ranging from 0.36 - 2.16% [20]. Meanwhile,
the TP53 p.R282G and p.Y234H have not been reported
to be present in the ICGC’s serous ovarian carcinoma
Table 2 Variant frequency in high grade serous ovarian carcinoma versus normal ovary
Gene/Variant frequency APC EGFR FGFR3 KDR KIT MET PDGFRA PIK3CA RET SMO STK11 TP53
Tumour 89% 67% 100% 89% 22% 11% 100% 11% 67% 22% 22% 100%
Normal 100% 30% 100% 70% 0% 10% 100% 0% 60% 10% 0% 0%
p value 0.4737 0.1789 1 0.5820 0.2105 1 1 0.4737 1 0.5820 0.2105 0.0001***
***Statistically significant value.
TP53 alterations are statistically significantly more frequent in serous ovarian carcinoma.
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cancer (0.11%) and renal cancer (0.25%) [20].
Discussion
In this study, we analyzed the base alteration status of
50 cancer-related genes using a targeted NGS approach
on nine high grade serous ovarian carcinoma and 10
normal ovaries. Since all cancers included in our study
were of high grade serous histology, we have avoided
any false correlation that might have resulted from a
study of mixed histological types. We observed that
transitions and substitutions were more frequent than
transversions and this is in agreement with other studies
on the patterns of somatic mutation in human cancer
genomes [21,22].
We found that TP53 alterations were the most com-
mon alterations identified in our local patients with high
grade serous ovarian carcinoma. In addition, the major-
ity of alterations identified in TP53 were predicted to be
deleterious and four of the mutations were the hotspot
mutations (p.R175H, p.H193R, p.Y220C and p.Y163C).
These deleterious mutations in TP53 were detected in
eight of the nine cancer samples. Our findings were in
agreement with other studies on high grade serous ovar-
ian carcinoma in which more than 80% of cases har-
boured TP53 mutations [12,15,17]. We could conclude
that TP53 mutations remain the most consistent gen-
omic feature in high grade serous ovarian carcinoma.
TP53 which encodes the tumor suppressor protein
p53, is among the most frequently mutated genes in hu-
man cancers [23]. The ubiquitous presence of TP53 mu-
tations in ovarian cancer has been suggested more than
20 years ago, particularly in those with serous histology
[24]. Whilst some tumor suppressor genes, such as APC
or BRCA1, are frequently deactivated by the frame shift
or nonsense mutations, the missense mutation is the pre-
dominant type of mutation in TP53 in human tumors
[25]. These mutations are identified mainly in exons 4–9,
which encode the DNA-binding domain of the protein
[26]. We identified seven mutations in TP53 DNA binding
domain from which six were missense mutations (86%)
and one silent alteration (14%). These observations con-
firmed previous findings that missense mutation was the
predominant alteration in TP53 in tumors [25].
A tumor cell with a TP53 missense mutation could re-
sult in full-length p53 proteins which have prolongedhalf-life and tend to accumulate in the tumor cells [25].
These mutant proteins were hypothesized to possess the
ability to influence tumor progression. Oren and Rotter
revealed that mutant p53 proteins can bind and deacti-
vate other related proteins such as p63 and p73 [27].
This tumorigenic activity of mutant p53 has been de-
scribed as gain-of-function (GOF), which was shown to
coerce tumor cells toward migration, invasion and me-
tastasis in mouse models as demonstrated by several
other studies [28,29]. A study by Kang and colleagues
also demonstrated that high grade serous ovarian cancer
patients with GOF mutant p53 frequently showed resist-
ance against platinum-based treatment and were prone
to distant metastasis [25].
We also observed low impact alteration in KIT and
STK11 exclusively in the tumor group which resulted from
base transversions. The KIT p.K546K, a silent alteration re-
sulted from A >G transversion at position 55593481, was
identified in sample T1 and was not detected in any ICGC
studies [20]. Another alteration in KIT, the p.M541L, is a
missense mutation resulting from A >C transversion at
position 55593464 found in sample T4, was also detected
in a patient with gastric cancer patient as reported in the
ICGC’s portal [20]. The STK11 p.F354L, a missense muta-
tion identified in sample T4 and T6, resulted from a C >G
transversion at position 1223125. To our knowledge, this
alteration has not been detected in any of the published
data from the consortium studies. The significance of these
low impact alterations is still yet to be identified. However,
the effort towards the development of personalized medi-
cine must be guided by a comprehensive look at the muta-
tional landscape of each tumor, hence these low impact
alterations should not be disregarded.
The small sample size is an obvious limitation of this
study and this could affect our interpretation of the re-
sults. Therefore a larger series of validation including
bigger sample size, different histological subtypes, inclu-
sion of germline DNA derived from the same sample are
indispensable in order to fully understand the genetic
events underlying this cancer. In addition, this panel is
targeting “hotspot” region of genes that are frequently
mutated in human cancer thus other infrequently altered
genes but of significance to serous ovarian cancers might
have been excluded such as ARID1A, BRCA1, BRCA2,
CSMD3, NF1, CDK12, FAT3 and GABRA6 [30]. Further-
more, variation in cancers may not be reflected in the
Table 3 Variant distribution of high grade serous ovarian carcinoma
Sample
ID/Gene
T1 T2 T3 T4 T5 T6 T7 T8 T9
APC - **112175770G > A **112175770G > A *112175770G > A *112175770G > A *112175770G > A *112175770G > A **112175770G > A *112175770G > A
EGFR *55249063G > A *55249063G > A *55249063G > A *55249063G > A *55249063G > A - - *55249063G > A -
FGFR3 **1807894G > A **1807894G > A **1807894G > A **1807894G > A **1807894G > A **1807894G > A **1807894G > A **1807894G > A **1807894G > A
KDR *55972974T > A *55972974T > A *55972974T > A - **55972974T > A **55972974T > A *55972974T > A *55972974T > A *55972974T > A
KIT *55593481A > G - - *55593464A > C - - - - -
MET - - - - - - - *116339672C > T -
PDGFRA **55141055A > G **55141055A > G **55141055A > G **55141055A > G **55141055A > G **55141055A > G **55141055A > G **55152040C > T
** 55141055A > G
**55141055A > G
*55152040C > T *55152040C > T *55152040C > T
PIK3CA - - - - - *178952020C > T - - -
RET *43613843G > T *43613843G > T *43613843G > T - - *43613843G > T *43613843G > T - **43613843G > T
SMO - *128845088A > G *128845088A > G - - - - - -
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Table 4 Deleterious mutations identified in high grade serous ovarian cancer samples
Sample ID Gene Mutation Codon change Protein change Type dbSNP ID/COSMIC ID transFIC prediction
T1 TP53 g.chr17:7578406C > T c.(523–525)CGC > CAC p.R175H SNP rs28934578 Driver mutation
T2 TP53 g.chr17:7578271T > C c.(577–579)CAT > CGT p.H193R SNP COSM10742 Driver mutation
T3 TP53 g.chr17:7578190T > C c.(658–660)TAT > TGT p.Y220C SNP rs121912666 Driver mutation
T4 TP53 g.chr17:7578442T > C c.(487–489)TAC > TGC p.Y163C SNP rs148924904 Strongly affecting mutation
T5 TP53 g.chr17:7578190T > C c.(658–660)TAT > TGT p.Y220C SNP rs121912666 Driver mutation
T6 TP53 g.chr17:7577094G > C c.(844–846)CGG > GGG p.R282G SNP rs28934574 Driver mutation
T8 TP53 g.chr17:7578406C > T c.(523–525)CGC > CAC p.R175H SNP rs28934578 Driver mutation
T9 TP53 g.chr17:7577581A > G c.(700–702)TAC > CAC p.Y234H SNP COSM11152 Driver mutation
SNP = single nucleotide polymorphism.
Figure 1 Deleterious mutations identified by targeted next generation sequencing in serous ovarian carcinoma. Representation of the
reads aligned to the reference genome of A) Tumor 1; B) Tumor 2; C) Tumor 3; D) Tumor 4; E) Tumor 5; F) Tumor 6; G) Tumor 8 and H) Tumor 9;
as provided by the Integrative Genomics Viewer V 2.3 software [19].
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Table 5 Comparison of TP53 deleterious mutations in this study with ICGC data
p.R175H p.H193R p.Y220C p.Y163C p.R282G p.Y234H
ICGC mutation ID MU7870 MU13250 MU4807 MU10836 MU34029 MU622929
Occurrences Affects 66 distinct
donors across 12
cancer projects
Affects 9 distinct donors
across 4 cancer projects
Affects 24 distinct donors










Occurrences in serous ovarian
cancer (ICGC)
6/278 (2.16%) 1/278 (0.36%) 4/278 (1.44%) 1/278 (0.36) None reported None reported
Occurrences in serous ovarian
cancer (this study)
2/10 (20%) 1/10 (10%) 2/10 (20%) 1/10 (10%) 1/10 (10%) 1/10 (10%)
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as gene expression (coding and non-coding), DNA
methylation as well as influence of genomic rearrange-
ments such as copy number and structural variations are
unable to be reliably addressed using this approach.Conclusions
Our findings revealed a relatively small number of som-
atic alterations in high grade serous ovarian cancer using
this commercially available cancer hotspot panel. An ex-
tensive somatic mutation screening targeting more genes
using the Ion Ampliseq™ Comprehensive Cancer Panel
(CCP) or whole exome sequencing might be a preferred
approach for future research, particularly in this disease.
Undoubtedly, the implementation of this hotspot panel
in routine molecular diagnostics for high grade serous
ovarian carcinoma definitely requires validation in larger
series of samples. Nevertheless, its superior performance
in identifying a wide range of genetic alterations simul-
taneously from a minute amount of DNA can facilitate
the evaluation of tumor-specific treatment susceptibility
and individual prognosis.Additional file
Additional file 1: Table S1. List of genes covered in the Cancer
Hotspot Panel v2. Table S2. Sequencing outputs from Ion Torrent PGM.
Table S3. Variant distribution of normal ovary. Figure S1. Category of
DNA substitution. Majority of substitution were of transition substitution
(purine-purine and pyrimidine-pyrimidine).Competing interests
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